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Background: Mantle cell lymphoma (MCL) is a relatively uncommon type of non-Hodgkin lymphoma. It develops
in the outer edge of a lymph node called the mantle zone. In contrast, IgG4-related dacryoadenitis and sialoadenitis
(IgG4-DS) is characterized by elevated serum IgG4 and persistent bilateral enlargement of lacrimal glands (LGs) and
salivary glands (SGs), with infiltration of IgG4-positive plasma cells. Recent studies indicated the importance of
differentiation between IgG4-DS and malignant lymphoma.
Case presentation: An 82-year-old man was suspected of IgG4-DS because of a high serum IgG level (2174 mg/dL)
and bilateral swelling of LGs and SGs. Lip biopsy and fine needle biopsy of submandibular gland were performed, and
subsequently, MCL was diagnosed through the histopathological findings.
Conclusions: MCL most commonly occurs in the Waldeyer ring, but rarely in the stomach, spleen, skin, LG, and SG. We
report an unusual case of MCL involving LGs and SGs mimicking IgG4-DS, which suggests that IgG4 testing may be
useful in the differentiation of IgG4-DS in the presence of bilateral swelling of LGs or SGs.
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Mantle cell lymphoma (MCL) is a relatively rare type of
non-Hodgkin lymphoma, accounting for ~3 % of malig-
nant lymphoma in Japan. MCL typically occurs in
middle-aged to older adults, with a marked male predi-
lection, and has a poorer prognosis compared with other
subtypes of non-Hodgkin lymphoma [1, 2]. MCL more
often presents in stage III/IV with lymphadenopathy,
hepatosplenomegaly, bone marrow involvement, and
leukemic spread [3]. Although the majority of MCLs
occur in lymph nodes, 25 % of patients have extranodal
involvement, with the Waldeyer ring (6.3 %), intestine
(5 %), stomach (2.5 %), orbit (2.5 %), and salivary gland
(2.5 %) [4]. Definitive diagnosis of MCL is predicated on
appropriate immunohistochemical staining with or* Correspondence: moriyama@dent.kyushu-u.ac.jp
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Clinicopathological characteristics of MCL are charac-
terized by overexpression of cyclin D1 protein; a feature
not seen in other similar-appearing lymphomas.
IgG4-related dacryoadenitis and sialoadenitis (IgG4-DS),
also known as Mikulicz’s disease, is a unique condition
characterized by enlargement of the lacrimal glands (LGs)
and salivary glands (SGs) caused by infiltration of lympho-
cytes. IgG4-DS has been considered to be a subtype of
Sjögren’s syndrome (SS) because of certain histopatho-
logical similarities, particularly lymphocytic infiltration [5].
However, IgG4-DS patients show elevated serum levels of
IgG4 and infiltrating IgG4-positive plasma cells in the
glandular tissues [6, 7]. Similar findings have also been
identified in other diseases such as autoimmune pan-
creatitis [8], interstitial pneumonia [9], retroperitoneal
fibrosis [10], and sclerosing cholangitis [11], and these
diseases are now referred to as IgG4-related disease
(IgG4-RD) [12]. IgG4-DS is now diagnosed by bothrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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Disease (2011)” and “Diagnostic Criteria for IgG4-
related Mikulicz’s Disease” approved by the Japanese
Society for Sjögren’s syndrome [13]. However, it is im-
portant to differentiate IgG4-RD from malignant tu-
mors (such as cancer and lymphoma) and similar
diseases (such as SS, primary sclerosing cholangitis,
Castleman’s disease, secondary retroperitoneal fibrosis
Wegener’s granulomatosis, sarcoidosis, and Churg–Strauss
syndrome) by histopathological examination of local le-
sions. Recently, we reported a case of marginal zone B-cell
lymphoma mimicking IgG4-DS [14]. Here, we report a rare
case of MCL involving multiple lymph nodes and bilateral
LGs and SGs mimicking IgG4-DS.
Case presentation
An 82-year-old man was referred to our institution with
bilateral swelling of the LGs and submandibular glands
(SMGs) in November 2008. He had previously attended
the ophthalmology department in our hospital with chief
complaints of bilateral swelling of LGs, which were diag-
nosed as IgG4-DS by these clinical findings and high
serum IgG (2174 mg/dL). LG biopsy was performed for
definitive diagnosis and 2 days later he visited our insti-
tution on referral from our ophthalmology department
for further evaluation of SMGs. He had several medical
histories of colonic cancer, hypertension, and cerebral
infarction.Fig. 1 Clinical findings before treatment. Bilateral swelling of LGs, SMGs, an
of biopsy (blue arrowheads) (d, e)Physical findings showed no fever (body temperature,
36.3 °C), blood pressure of 132/78 mmHg, no weight
loss, and no nocturnal sweating. He was aware of dry
mouth (unstimulated salivary flow rate, 0.4 mL/
15 min). Bilateral SMGs, sublingual glands (SLGs), and
labial salivary glands (LSGs) were elastic, hard and
swollen without pain (Fig. 1). Several cervical lymph
nodes were enlarged. Computed tomography (CT)
showed marked swelling of bilateral LGs and SMGs
(Fig. 2a). F-18 fluorodeoxyglucose positron emission
tomography demonstrated abnormal multiple accumu-
lations in the LGs (SUVmax, 7.14), SMGs (SUVmax,
6.83), and several systemic lymph nodes (SUVmax,
3.45–4.74), including in the neck and mediastinum
(Fig. 2b).
He had a low hemoglobin level (13.4 g/dL), red blood
cell count of 4.57 × 106/mm3, white blood cell count of
7150/mm3 (neutrophils 45.5 %, lymphocytes 35.0 %,
monocytes 9.5 %, eosinophils 1.0 %, and basophils
0.5 %), and platelet count of 179 × 103/mm3. His C-
reactive protein level was 0.23 mg/dL. The serum soluble
interluekin-2 receptor concentration was abnormally high
(2251.4 U/mL). Immunological tests were negative for
the anti-SS-A/B antibody and the anti-thyroid peroxid-
ase antibody, but positive for rheumatoid factor. Serum
levels of IgA, IgM, and IgE were within normal limits
(354 mg/dL, 167 mg/dL, and 44 IU/mL, respectively),
but his serum IgG level was elevated (2174 mg/dL).d SLGs (yellow arrowheads) (a–c). Multiple swelling of LSGs at the time
Fig. 2 Imaging findings before treatment. a CT findings indicating swelling of LGs, SMGs and SLGs (white arrowheads). b FDG-PET indicating
abnormal multiple accumulations in SMGs and LGs (white arrowheads) and in multiple systemic lymph nodes (white arrows)
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metrical swelling of at least two pairs of LGs and major
SGs for at least 3 months. We thus additionally exam-
ined serum IgG4 and it was in the normal range
(43.7 mg/dL). We performed LSG biopsy and fine nee-
dle biopsy (FNB) of the left SMG in addition to LG
biospy to check if LSG and SMG were the same disease.
Histologically, all sections showed severe uniformFig. 3 Histological findings in LSG. Marked lymphoplasmacytic infiltration w
stained with hematoxylin and eosin (HE) (a, b), anti-CD3 (c), anti-CD5 (d), a
IgG4 (j) monoclonal antibodiesinfiltration of lymphoplasmacytes, without lymphoid fol-
licular formation. The plasmacytoid cells showed nuclear
pleomorphism. Immunohistochemical staining showed
monotypic predominance of kappa-light chain and no in-
filtration of IgG4-positive plasma cells. The infiltrating
lymphocytes were positive for B-cell markers (CD20 and
CD79a), CD5, bcl-2, and cyclin D1, but negative for T-cell
markers (CD3) and CD10 (Fig. 3).ith hyperplastic lymphoid follicles. The infiltrating lymphocytes were
nti-CD10 (e), anti-CD79a (f), anti-bcl-2 (g), anti-cyclin D1 (h), IgG (i), and
Table 1 Differential diagnosis of lymphoma in immunostaining
CD3 CD5 CD10 CD20 CD79a Cyclin D1 bcl-2 UCHL-1
DLBL − − +/− + + − +/− −
FL − − + + + − + −
MALT
lymphoma
− − − + + − + −
MCL − + − + + + + −
This case − + − + + + + −
DLBL diffuse large B-cell lymphoma, FL follicular lymphoma,
MALT mucosa-associated lymphoid tissue
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confirmed a diagnosis of MCL. The patient underwent
radiotherapy (20 Gy/10 Fr) and chemotherapy (600 mg
rituximab, four times). Although swelling of the LGs and
SMGs diminished markedly, it became intractable to
treatment at 1 year following therapy and finally termi-
nated in patient death in November 2011.
Conclusions
MCL is recognized as an aggressive lymphoma for which
the median survival of patients is ~3 years [15]. The clin-
ical and prognostic implications of initial presentation of
MCL in the hard palate are currently unknown. MCL is
presently staged by using a modified Ann Arbor system
[16]. Stage I consists of the involvement of a lymphoid
structure or lymph node region, whereas stage II exhibits
the involvement of two or more regions on the same side
of the diaphragm. Stage III disease represents the involve-
ment of structures or lymph node regions on both sides of
the diaphragm, whereas stage IV disease is characterized
by diffuse disseminated involvement of one or more extra-
lymphatic organs, such as bone marrow, liver, or lung.
Our patient had stage II disease at presentation, with
lesions of the LGs, SGs, and cervical lymph nodes.
Immunophenotypically, the neoplastic lymphocytes usu-
ally express CD5, CD20, CD43, and FMC-7, but not CD10
or Bcl-6 [17]. The lymphocytes are typically negative for
CD23 expression, but on occasion, they may be weakly
positive. All lymphocytic specimens typically express Bcl-1,
including the rare specimen that is CD5 negative [18]. An
important, but less-recognized fact is that almost all lym-
phocytes are Bcl-2 positive. Several studies have reported
that immunohistochemical detection of cyclin D1 is usefulTable 2 MCL involved in LGs and SGs
Case Sex Age Regions
1 Female 42 LG, PG, SMG Bilater
2 Male 52 LG, PG, SMG Bilater
3 Male 82 LG, PG, SMG Bilater
SLG, LSG
MCL mantle cell lymphoma, LG lacrimal glands, SG salivary gland, PG parotid gland,for diagnosis of MCL [19–21]. In this case, we confirmed
that the patient was positive for CD-5 and cyclin D1 and
negative for CD-10. This suggested that this case was con-
sistent with MCL (Table 1).
Larry et al. [4] reported clinical characteristics of pri-
mary MCLs. According to their study, 20 of 80 MCLs in-
volved extranodal sites, while only two involved SGs. To
the best of our knowledge, two cases of MCL were re-
ported to involve bilateral LGs and parotid glands (Table 2)
[22, 23]. Therefore, the present case report of MCL occur-
ring in bilateral LGs and SMGs is rare, and these clinical
findings were similar to those in IgG4-DS. We thus add-
itionally examined serum IgG4 levels and performed both
LSG biopsy and FNB of swelling salivary glands.
IgG4-DS is now recognized as a new emerging dis-
order, characterized by high serum IgG4, marked infil-
tration of IgG4-positive plasma cells, and severe fibrosis
with hyperplastic ectopic germinal centers in LGs and
SGs. We recently proposed “Comprehensive Diagnostic
Criteria for IgG4-RD” [9]. IgG4-RD can be diagnosed
using these criteria combined with organ-specific cri-
teria. If a diagnosis of IgG4-DS is probable or possible
based on these criteria, it can be confirmed according to
the “Diagnostic Criteria for IgG4-related Mikulicz’s
Disease” approved by the Japanese Society for Sjögren’s
Syndrome in 2008, which include the following items: (i)
persistent (>3 months) symmetrical swelling of more
than two LGs and major SGs; (ii) raised serum levels of
IgG4 (>135 mg/dL); and (iii) infiltration of IgG4-positive
plasma cells in the tissue (IgG4-positive plasma cells/
IgG-positive plasma cells >0.4) by immunostaining. For
a positive diagnosis of IgG4-DS, any two of these three
criteria must be fulfilled, including item (i). The present
case met criterion (i), and IgG4-DS was therefore sus-
pected. However, biopsy of the local lesion is recom-
mended for differential diagnosis from other disorders,
including sarcoidosis, Castleman’s disease, Wegener’s
granulomatosis, lymphoma, and cancer. We therefore
performed LSG biopsy and FNB of SMGs, resulting in a
definitive diagnosis of MCL. These results suggest that
biopsy of the swollen lesion is essential for a definitive
diagnosis of IgG4-DS. Moreover, we recently reported
the importance of the utility of SMG incisional biopsies
[24]. In conclusion, we emphasize the importance of
performing thorough biopsy and serum IgG4 testingAnn Arbor staging Author Year
al II Palaniswamy [22] 2009
al II Sagar [21] 2011
al IIE This case 2015
SMG submandibular gland, SLG sublingual gland, LSG labial salivary gland
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SG swelling. Therefore, we suggest that accurate and
rapid diagnosis leads to effective treatment.
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